Desmopressin

Dosing from the Literature

Published for central diabetes insipidus: label doses of 0.05 mg twice a day by mouth to start (most trial patients on 0.1–0.8 mg a day), 10–40 µg a day by nasal spray in adults, or 2–4 µg a day by injection. Not published: a single dose that fits everyone, because every label sets it person by person.

Each row is a US label or a trial. Four of the labels are for products Drugs@FDA lists as marketed; Stimate’s was revised in July 2026, though Drugs@FDA lists Stimate as discontinued; Nocdurna’s and Noctiva’s are the labels of two discontinued nocturia products (Drugs@FDA). The labels set the dose for each person and pair it with limits on fluid intake (DDAVP Tablets label; DDAVP Injection label). The rows record doses as published, for the conditions named; they are not recommendations.

What It Is

Desmopressin is a synthetic analogue of arginine vasopressin, the pituitary hormone that controls how much water the kidneys keep (DDAVP Tablets label). Its chemical name, 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin, records two changes to the natural hormone: the first unit lacks its amino group (the “deamino” of dDAVP), and the arginine at position 8 is the mirror-image D form (DDAVP Injection label; Manning et al., 2012). The result is a ring of six units closed by a sulfur–sulfur bridge, with a three-unit tail: Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH₂, C46H64N14O12S2, 1,069.2 Da (PubChem). The drug is its acetate salt, 1,183.34 Da as the trihydrate (DDAVP Injection label).

Czech chemists reported its synthesis in 1967 (Zaoral et al., 1967), and in 1968 a team including two of them reported its effects in animals and in patients with diabetes insipidus (Vávra et al., 1968). It was made in Prague and later licensed to Ferring, and has been marketed as Minirin (Manning et al., 2012). FDA approved DDAVP as a nasal solution on February 21, 1978 (NDA 017922, now held by Ferring), then the injection in 1984 (NDA 018938) and the tablets in 1995 (NDA 019955) (Drugs@FDA). In 1977 a Milan group reported that IV desmopressin raised factor VIII in people with mild hemophilia and von Willebrand disease, and that tooth extractions and major operations were carried out successfully in eight of them (Mannucci et al., 1977); WHO added it to its list of essential medicines in 1991 (Mannucci & Siboni, 2024).

Central diabetes insipidus, the condition it was first tested in, is not a form of diabetes mellitus: the pituitary releases too little vasopressin, and large volumes of dilute urine follow (Atila et al., 2026). In 2022 an international working group proposed renaming it arginine vasopressin deficiency, because patients were coming to harm (Arima et al., 2022); in a survey of 1,034 patients, 80% had met health workers who confused it with diabetes mellitus (Atila et al., 2022). Desmopressin is the mainstay of its treatment (Atila et al., 2026).

In the US it is sold as DDAVP tablets and injection, as generic tablets, injections and nasal sprays, and since February 2026 as Desmoda, an oral solution from Eton Pharmaceuticals (Drugs@FDA). Desmoda’s label rests its effectiveness on studies of the tablets (Desmoda label), and an Eton-funded study in 75 healthy adults found the solution and the tablets bioequivalent (Christensen et al., 2026). Several brands are discontinued: the original DDAVP nasal spray, Stimate, and the two products approved for night-time urination, Noctiva (2017) and Nocdurna (2018) (Drugs@FDA). PubMed returns 6,794 records for “desmopressin” (searched October 4, 2026); 4,571 are indexed under its subject heading, and 292 of those are tagged as randomized controlled trials.

Mechanism of Action

The findings below come from the labels, from rat bioassays and receptor data summarized in a 2012 review, from cells engineered to carry single human receptors, from human blood-vessel cells grown in the lab, from a 2026 clinical review and from one registered NIH study (DDAVP Injection label; Manning et al., 2012; Saito et al., 1997; Kaufmann et al., 2000; Atila et al., 2026; NCT04569591).

• V2 receptors in the kidney (aquaporin-2) — Desmopressin’s antidiuretic effect runs through vasopressin V2 receptors, raising water reabsorption in the kidney and so reducing urine output (desmopressin nasal spray label, Apotex). Vasopressin’s V2 receptors work by inserting aquaporin-2 water channels into the kidney’s collecting ducts (Atila et al., 2026). The labels state it is ineffective in nephrogenic diabetes insipidus (DDAVP Tablets label), the form in which the kidney does not respond to the hormone, now named arginine vasopressin resistance (Arima et al., 2022).
• Longer action, little pressure effect (the two structural changes) — The changes from vasopressin lengthened its action and reduced its effects on blood pressure and smooth muscle relative to its antidiuretic effect (DDAVP Injection label). In rat assays, vasopressin is about equally antidiuretic and pressor (a ratio of 0.9), while desmopressin’s antidiuretic-to-pressor ratio is 3,000 (Manning et al., 2012). Vasopressin itself has a half-life of about 10 minutes in the blood (Atila et al., 2026).
• Less selective in human receptors (V1b, oxytocin receptor) — In receptor tests, desmopressin bound the V1b receptor more tightly than the V2 receptor (Ki 5.84 against 65.9 nM), and in cells carrying the human receptors it fully activated both (Saito et al., 1997). A 2012 review of receptor data concludes it is not a selective V2 agonist in humans, with high affinity for the human V1b receptor and somewhat less for the oxytocin receptor, though in rats it is relatively V2-selective (Manning et al., 2012). An NIH study gives 10 µg IV to raise ACTH from pituitary tumors in Cushing’s disease before PET imaging (NCT04569591).
• Factor VIII and von Willebrand factor (endothelial V2, cAMP) — In human lung blood-vessel cells, which carry V2 receptors, vasopressin and desmopressin released von Willebrand factor through cAMP; a V2 blocker stopped it, and umbilical-vein cells responded only after V2 receptors were added (Kaufmann et al., 2000). In people, factor VIII rises within 30 minutes of an IV dose and peaks at 90 minutes to two hours; how long the effect lasts depends on factor VIII’s half-life, about 8–12 hours, and doses given more often than every 48 hours can produce smaller responses (DDAVP Injection label).
• No fast off-switch (why sodium falls) — Its antidiuretic action is not subject to the rapid feedback that low blood osmolality exerts, so even modest drinking can lead to water retention and dilutional hyponatremia (Atila et al., 2026).
• Absorption and clearance — By mouth, about 0.16% of a dose reaches the blood compared with an IV dose, and about 5% compared with a nasal dose; blood levels peak about 0.9 hours after a tablet (1.5 hours after a nasal dose) and fall with a half-life of 1.5–2.5 hours (DDAVP Tablets label). A nasal dose is 3.3–4.1% absorbed (Stimate label). After 2 µg IV, the terminal half-life is 2.8 hours and 52% of the dose leaves unchanged in the urine within 24 hours; it is not metabolized by the liver’s CYP450 enzymes, and in severe kidney impairment the half-life is 8.7 hours (DDAVP Injection label). For the oral solution the half-life is 3.6 hours, and a high-fat meal cut absorption by 64% (Desmoda label).

What the Research Shows

The reviews and the lab and animal findings are here; the individual human studies are under Human Data (Hahn et al., 2025; Desborough et al., 2017).

• Replacing vasopressin (the use on its tag) — Desmopressin is the mainstay of treatment for arginine vasopressin deficiency (Atila et al., 2026). The tablet label’s evidence for this use is dose-response studies, in which 0.025 to 0.4 mg produced clinically significant antidiuretic effects, and long-term follow-up of 46 patients for 12 to 44 months (DDAVP Tablets label); the published patient series go back to 1968 (Vávra et al., 1968; Marek et al., 1978).
• Animal toxicology on the labels — Oral doses up to 0.2 mg/kg a day for 6 months in dogs and rats produced no significant drug-related toxicity, and an IV dose of 2 mg/kg in mice had no effect (DDAVP Tablets label). Pregnant rats given up to 241 µg/kg a day into a vein and rabbits given up to 200 µg/kg a day under the skin showed no effects on maternal or fetal survival or fetal form (DDAVP Injection label). Whether it causes cancer has not been studied (DDAVP Injection label).
• Bedwetting in children — A 2025 Cochrane review of 95 studies and 8,473 children found desmopressin may reduce wet nights by 1.81 a week compared with placebo (16 studies, 1,267 children, low certainty) and probably helps more children reach 14 dry nights in a row (risk ratio 3.18; 11 studies, 922 children, moderate certainty). By the end of treatment it may do about as well as a bed alarm (low- or very-low-certainty evidence), but alarm therapy may leave more children dry at follow-up (moderate certainty) (Hahn et al., 2025).
• Night-time urination in adults — A review of 14 trials in 2,966 men found that over up to 3 months desmopressin may have a similar effect to placebo on night-time voids (a difference of 0.46, with a confidence interval crossing zero; low quality) and over 3–12 months may cut them by 0.85 a night (low quality); added to an alpha-blocker, it gave a small reduction that the authors judged unimportant (Han et al., 2018).
• Bleeding disorders — The 2021 international guideline on von Willebrand disease includes recommendations on desmopressin trials to determine therapy (Connell et al., 2021). Responses fall with repeated doses, and World Federation of Hemophilia guidelines cap use at two doses a day for at most three days, followed by factor VIII or von Willebrand factor products as needed (Mannucci & Siboni, 2024).
• Surgery in people without a bleeding disorder — A 2017 Cochrane review of 65 trials (3,874 participants) found that in adult heart surgery desmopressin may slightly reduce the red cells transfused (by 0.52 units; 14 trials, 957 participants), and that across settings it probably makes little or no difference to how many people are transfused (risk ratio 0.96; 25 trials, 1,806 participants). The authors judged the reductions in heart surgery unlikely to be clinically important (Desborough et al., 2017).
• Memory — Studies from 1981 to 1986 reported mixed results, and a 2019 analysis traces how interest in the vasopressin–memory hypothesis declined as shortcomings in its experimental foundations were recognized (Leng et al., 2019). The studies are under Human Data.

Human Data

Desmopressin has been given to patients since 1968 (Vávra et al., 1968). PubMed tags 292 records under its subject heading as randomized controlled trials (searched October 4, 2026); the points below cover the studies behind its labels, the largest safety studies, and other uses people cite. ClinicalTrials.gov lists 127 studies with desmopressin as an intervention, 16 of them with an active status (searched October 4, 2026).

• Central diabetes insipidus, 30 patients over 3–10 years (Marek et al., 1978) — A report with Zaoral among its authors followed 30 patients treated with 7–42 µg a day by nose, in one to three doses. Urine output, 7,600 to 28,000 mL a day before treatment, fell below 2,000 mL in 21 (70%) and to 2,000–4,000 mL in 8 (26.6%); in one patient it fell from 20,000 mL but not below 8,000 mL. The authors saw no loss of potency and no harmful effects, and all the patients preferred it to their earlier treatment.
• Tablets, on the label (DDAVP Tablets label) — In dose-response studies in diabetes insipidus, oral doses of 0.025 to 0.4 mg produced clinically significant antidiuretic effects, lasting up to 12 hours at 0.4 mg. The 46 patients treated with tablets for 12 to 44 months showed no lessening of effect, no antibodies to desmopressin and no increase in blood pressure. In 36 water-loaded healthy men, 0.2 and 0.4 mg by mouth every 8 hours produced 84–99% and 95–110% of the effect of 0.01 mg by nose.
• How long a dose lasts, two crossover studies in 13 patients (Juul et al., 2011) — In two three-way crossover studies in 13 patients with central diabetes insipidus, funded by Ferring, with two of the three authors at the company, desmopressin was given into a vein at 30, 60 and 125 ng in one and at 125, 250 and 500 ng in the other; the 125, 250 and 500 ng doses held back urine for 4, 8 and 11 hours. Adverse events were classed as unrelated or unlikely related to the drug, and none was serious.
• Low sodium in long-term treatment (Behan et al., 2015; Pedersen et al., 2024) — In 147 patients at a tertiary referral center, 137 of them with normal thirst, mild hyponatremia (131–134 mmol/L) was the most common outpatient abnormality among those with normal thirst, in 27%; 14.6% of them had sodium of 130 mmol/L or less, and 5.8% were admitted for complications of hyponatremia (Behan et al., 2015). In 222 patients at a Copenhagen hospital, the median daily dose, converted to tablet terms, was 600 µg in the 7 with congenital disease and 200 µg in those with acquired disease, a difference the authors call uncertain because the congenital group was small; in the previous 12 months, 66 of 215 patients (30.7%) had sodium below 136 mmol/L and 20 (9.3%) below 131, with no difference in risk between nasal and oral forms (Pedersen et al., 2024).
• The patients’ own account, 1,034 people (Atila et al., 2022) — In an international web survey of people with central diabetes insipidus (91 children, 943 adults), 260 (26%) of the 994 on desmopressin reported hyponatremia that led to a hospital stay. These are patients’ own reports; in the referral center’s records above, 5.8% of patients with normal thirst had been admitted for complications of low sodium (Behan et al., 2015). Those who routinely skipped or delayed a dose to let a bout of urination clear excess water reported it less often (odds ratio 0.55). Of 535 who had been in hospital for any reason, 71 (13%) said they were not given desmopressin while fasting and without IV fluids, and reported symptoms of dehydration.
• Bedwetting, 340 children (DDAVP Tablets label) — In two double-blind, placebo-controlled trials in children aged 5–17 with primary nocturnal enuresis (72% boys), wet nights fell over two weeks by 10% on placebo and by 27%, 30% and 40% on 0.2, 0.4 and 0.6 mg a day. In a six-month open extension in 230 children, 56% had at least half as many wet nights as at baseline and 38% were completely or nearly dry; 86% were raised to the highest dose.
• Nocturia, Nocdurna’s trials (Nocdurna label; Sand et al., 2013; Weiss et al., 2013) — Two 3-month, randomized, double-blind, placebo-controlled trials established Nocdurna’s efficacy. In a trial of 237 women with night-time overproduction of urine (121 of them on Nocdurna), 27.7 µg under the tongue cut night-time voids from 2.9 by 1.5, against 1.2 on placebo; in a trial of 230 such men (102 on Nocdurna), 55.3 µg cut them from 3.0 by 1.3, against 0.9 (Nocdurna label). In the full published trials, both sponsored by Ferring (NCT01223937; NCT01262456), the difference from placebo was 0.22 voids a night with 25 µg in a trial of 261 women (Sand et al., 2013) and 0.37 and 0.41 with 50 and 75 µg in a trial of 385 men (Weiss et al., 2013); both counts include the placebo groups. Nocdurna’s two strengths carry 25 and 50 µg of desmopressin (27.7 and 55.3 µg as the acetate); 75 µg was not one of them (Nocdurna label).
• Nocturia, Noctiva’s trials (Kaminetsky et al., 2018; Noctiva label) — Two 12-week, randomized, double-blind, placebo-controlled Phase 3 trials gave 1,333 adults aged 50 or older a nasal spray of 0.83 or 1.66 µg or placebo: night-time voids fell by 1.4 and 1.5, against 1.2, and 37.9% and 48.7%, against 30.3%, halved them. Hyponatremia (125 mmol/L or less, or under 130 with symptoms) occurred in 0% on 0.83 µg, 1.1% on 1.66 µg and 0.2% on placebo (Kaminetsky et al., 2018). Both trials were sponsored by Serenity Pharmaceuticals (NCT01357356; NCT01900704), and two of the report’s seven authors were from the company (Kaminetsky et al., 2018). Noctiva, made for Serenity, was approved in 2017; its label reports the 1,045 trial patients whose night-time urination came from making too much urine at night, and states that the 0.83 µg dose did not meet all prespecified efficacy endpoints (Noctiva label; Drugs@FDA).
• Hemophilia A and von Willebrand disease (Mannucci et al., 1977; Stimate label) — In the 1977 Milan series, 0.3 µg/kg IV before dental surgery raised factor VIII two- to threefold in 4 patients with moderate or mild hemophilia, two of whom still needed plasma concentrates to control oozing; at 0.4–0.5 µg/kg in patients starting from 9% or more, factor VIII rose four- to sixfold, and tooth extractions and major operations were carried out successfully in 6 people with mild hemophilia and 2 with von Willebrand disease (Mannucci et al., 1977). In Stimate’s outpatient trials, the spray stopped every recorded bleed in 2 of 5 patients with hemophilia A and 45% (14 of 31) of bleeds in the others, and every bleed in 75% of 16 patients with von Willebrand disease (Stimate label).
• Under the skin (Blanco et al., 2006; Rodeghiero et al., 1996) — In a retrospective multicenter study, infants with central diabetes insipidus given desmopressin under the skin kept their outpatient blood sodium in a narrower range, with more of their readings in the normal range, than infants given lysine vasopressin or desmopressin by nose; neither group had significant complications (Blanco et al., 2006). In a prospective multicenter study of home treatment lasting 12 months (range 6–17), 43 of 100 people with von Willebrand disease and 36 of 69 with mild or moderate hemophilia A injected concentrated desmopressin under the skin themselves. By the patients’ own scoring, the response was excellent or good in 94% of treatments, heavy menstrual bleeding aside, and in 86% of treated episodes of heavy menstrual bleeding; 10 treatments failed, 7 of them needing hospital care, and mild flushing, with or without headache, came with about 30% of treatments (Rodeghiero et al., 1996).
• Bleeding on antiplatelet drugs, 54 patients (Desborough et al., 2023) — In a UK Phase 2 feasibility trial, people with a bleed in the brain who were taking antiplatelet drugs got a single 20 µg IV dose or placebo. Death or dependency at 90 days occurred in 6 of 27 on desmopressin and 10 of 27 on placebo; the trial was built to test whether recruitment was feasible, and the authors call for a definitive trial.
• Memory, 1981–1986 (Weingartner et al., 1981; Beckwith et al., 1984; Jenkins et al., 1982; Guard et al., 1986; Peabody et al., 1986) — A 1981 report in Science described adults with and without cognitive impairment learning more effectively after several days of desmopressin (Weingartner et al., 1981), and a 1984 study found better sentence memory in young men but not women (Beckwith et al., 1984). Others found no benefit in healthy people or patients with memory disorders (Jenkins et al., 1982), or after 15 days of 20 µg a day by nose in 10 healthy students, against 20 on placebo (Guard et al., 1986). In a double-blind, placebo-controlled study of 14 people with Alzheimer’s disease, the desmopressin group got doses by nose rising to 180 µg a day over 3 weeks; 3 of 31 measures showed an effect, all of them mood or social ratings (a depression scale and two subscales of a geriatric rating scale) rather than memory, by amounts the authors judged probably too small to matter clinically, and one patient became hyponatremic (sodium 120) and confused at 180 µg (Peabody et al., 1986).
• Blood values in athletes, 8 men (Sanchis-Gomar et al., 2010) — In a crossover study, physically active men drank 1.5 L of water with or without 4.3 µg/kg of desmopressin; with it, hematocrit, hemoglobin and the OFF-hr score fell, values anti-doping tests use to detect blood doping. The authors argued it belonged on WADA’s prohibited list.
• Registered, not yet reported — Phase 3 trials of desmopressin to prevent too-fast correction of severe hyponatremia (260 planned; NCT06020495) and against bleeding after a kidney biopsy (NCT05467033) are listed as recruiting, though their estimated primary completion dates, September 30 and August 31, 2026, have passed and both records were last updated in May 2025. A Phase 3 pilot against bleeding in people with kidney disease having surgery is recruiting (NCT06337838), and a Phase 4 trial gives it during surgery for complex sellar tumors to prevent high sodium (152 planned; NCT07712328) (ClinicalTrials.gov, searched October 4, 2026; records re-read October 5, 2026).

The evidence meter on the Desmopressin card reads “Approved drug” because FDA approved it as antidiuretic replacement therapy in central diabetes insipidus, the hormone replacement its tag stands for (DDAVP Tablets label; Drugs@FDA). The tablet label describes dose-response and long-term studies for that use, and no placebo-controlled trial (DDAVP Tablets label).

Pipeline

• Phase 4, prophylactic intraoperative desmopressin in complex sellar-tumor surgery (152 planned) (NCT07712328), primary completion est. May 2028
• Phase 3 pilot, desmopressin and/or tranexamic acid before surgery in kidney patients (BRACKETS, Hamilton Health Sciences, 100 planned) (NCT06337838), primary completion est. Feb 2027
• Phase 3, prolonged desmopressin infusion in high-bleeding-risk cardiac surgery (REDES-BLEED, 112 planned; not yet recruiting, though its July 2025 start date has passed and the record was last updated in June 2025) (NCT07012837), primary completion est. Jul 2027
• Phase 2, desmopressin stimulation test in ACTH-dependent Cushing syndrome (NIDDK, 140 planned) (NCT06635629), primary completion est. Oct 2028
• Randomized trial of desmopressin by nose before sinus surgery for nasal polyps (Services Institute of Medical Sciences, Pakistan, 174 planned; not yet recruiting) (NCT07855315), primary completion est. Oct 2027
• Desmopressin-stimulated FDG-PET to find pituitary tumors missed by MRI in Cushing’s disease (NINDS, 22 planned) (NCT04569591), primary completion est. Feb 2028

Reconstitution & Storage

There is nothing to reconstitute: every approved form comes ready to use, as tablets of 0.1 and 0.2 mg (DDAVP Tablets label), an oral solution of 0.05 mg/mL (Desmoda label), nasal sprays of 10 µg per spray (desmopressin nasal spray label, Apotex) and 150 µg per spray (Stimate label), and an injection solution of 4 µg/mL in 1 mL ampules and 10 mL vials (DDAVP Injection label).

• IV infusion for bleeding disorders — The injection label dilutes the weight-based dose in saline, 10 mL for a patient of 10 kg or less and 50 mL above that, infused over 15–30 minutes; for diabetes insipidus it is given undiluted (DDAVP Injection label).
• Storage on the labels — The injection is kept refrigerated at 2–8 °C (DDAVP Injection label); the tablets at 20–25 °C (DDAVP Tablets label); the generic spray at 25 °C, with excursions of 15–30 °C (desmopressin nasal spray label, Apotex); Stimate at 20–25 °C, discarded 6 months after opening (Stimate label); Desmoda at 2–25 °C, discarded 120 days after first opening (Desmoda label).
• Spray counts — A generic bottle delivers 50 sprays of 10 µg and a Stimate bottle 25 sprays of 150 µg; the generic label discards a bottle after 50 sprays because later sprays may deliver substantially less (desmopressin nasal spray label, Apotex; Stimate label).
• Lab-reagent powder — Laboratory-reagent desmopressin is sold as freeze-dried powder labelled for research use only and not for human or animal consumption; the listing read for this page gives its storage as −20 °C (one supplier listing, read October 4, 2026). No study has tested such a product in people.

→ Peptide Calculator — vial-to-syringe math

Side Effects & Risks

• Who is most at risk (the labels) — Children and older adults; people with cystic fibrosis, heart failure, kidney disorders or habitual or psychogenic polydipsia; and people on drugs that also lower sodium, among them tricyclic antidepressants, SSRIs, NSAIDs, opioid painkillers, chlorpromazine, carbamazepine, lamotrigine, thiazide diuretics and chlorpropamide (DDAVP Injection label). Hyponatremic seizures have been reported with oxybutynin and imipramine taken alongside it, and the labels contraindicate it when creatinine clearance is below 50 mL/min (DDAVP Tablets label).
• How often, in long-term use — Mild hyponatremia in 27% and sodium of 130 mmol/L or less in 14.6% of the 137 outpatients with normal thirst in a 147-patient series (Behan et al., 2015); sodium below 136 mmol/L in the previous year in 66 of 215 patients (30.7%) in a 222-patient series (Pedersen et al., 2024); and a hospital stay for it reported by 26% of 994 patients surveyed (Atila et al., 2022).
• In a large health-plan cohort — In a nationwide health-plan database (mean age 70), 3,137 new users of older desmopressin forms had hyponatremia diagnosed at 146 per 1,000 person-years, against 11 among matched new users of the bladder drug oxybutynin, a 13-fold higher rate (hazard ratio 13.19); only 20% had a baseline sodium on record (Fralick et al., 2019).
• In the nocturia trials — Sodium of 130–134 mmol/L occurred in 17% of men on 55.3 µg, against 3% on placebo, and 125 or less in 3 men (2%); women on 27.7 µg had 130–134 in 7% and 126–129 in 4%, against 4% and 0% on placebo, and the women’s dose is lower because women had more hyponatremia at 55.3 µg in the trials (Nocdurna label). On Noctiva’s 1.66 µg dose, five patients reached 125 mmol/L or less, all aged 65 or older (Noctiva label).
• In children treated for bedwetting — A 2007 review found 48 published case reports of hyponatremia in children with enuresis, all on the nasal form, and 151 postmarketing cases, 145 on the nasal form and 6 on tablets (Robson et al., 2007). The current nasal spray label excludes bedwetting because postmarketing reports showed more hyponatremia and hyponatremic seizures with the spray than with tablets (desmopressin nasal spray label, Apotex). The 2025 Cochrane review lists minor effects including dizziness, headache, mood changes, stomach discomfort and hyponatremia, and one report of a convulsion (Hahn et al., 2025).
• Correcting low sodium too fast — In a case series of 15 hospital patients with symptomatic desmopressin-linked hyponatremia, the 13 whose desmopressin was stopped and who got IV saline had their sodium rise by a mean of 37.1 mEq/L in two days; 23% died and 69% had severe brain damage. The two in whom desmopressin was continued alongside hypertonic saline rose by 11.0 mEq/L and recovered without neurological damage (Achinger et al., 2014).
• Other effects on the labels — Headache, nausea, flushing and mild abdominal cramps with large doses (DDAVP Tablets label); nasal congestion, nasal inflammation (rhinitis) and nosebleeds with the sprays (desmopressin nasal spray label, Apotex); falls or rises in blood pressure, with a faster heart rate; fluid retention that can worsen heart failure; and allergic reactions, including fatal anaphylaxis after IV doses (DDAVP Injection label). In type IIB von Willebrand disease it can clump platelets, lower the platelet count and possibly cause clots (DDAVP Injection label).
• With GLP-1 drugs — Case reports describe people with arginine vasopressin deficiency who needed less desmopressin after starting semaglutide or liraglutide (Nakhleh et al., 2024), and a woman on tirzepatide whose sodium fell to 121 mmol/L (Caputo, 2026); see Commonly Stacked With.
• Product problems — In July 2020 Ferring recalled DDAVP Nasal Spray, Stimate and a third desmopressin nasal spray as superpotent, a Class I recall (FDA enforcement reports, 2020).
• Pregnancy and breastfeeding — Decades of use in pregnancy have not identified a drug-associated risk of major birth defects or miscarriage, lab studies with human placenta show little transfer, and breastfeeding is not expected to expose the infant to clinically relevant amounts (DDAVP Injection label). Nocdurna’s label advised against it for night-time urination in pregnancy (Nocdurna label).
• What has not been studied — Its cancer-causing potential has not been tested, and no in vivo drug-interaction studies have been done (DDAVP Injection label).
• WADA — Named on the 2026 Prohibited List under S5, Diuretics and masking agents, which are prohibited at all times, in and out of competition; every substance in the class is a Specified Substance (World Anti-Doping Agency, 2026). In eight active men, desmopressin with 1.5 L of water lowered hematocrit and hemoglobin, values used to detect blood doping (Sanchis-Gomar et al., 2010).

Bloodwork & Monitoring

What the labels list, by use (DDAVP Injection label; DDAVP Tablets label):

• Blood sodium — Normal before starting or resuming, then measured within 7 days and about 1 month after starting and periodically during treatment, more often in people 65 and older or at higher risk (DDAVP Injection label). Nocdurna’s label set the same schedule (Nocdurna label).
• Urine volume and osmolality (diabetes insipidus) — Before and intermittently during treatment, with plasma osmolality in some cases (DDAVP Injection label; DDAVP Tablets label).
• Clotting tests (bleeding disorders) — Factor VIII coagulant activity above 5% and no factor VIII antibodies before use in hemophilia A, with sodium and aPTT; in von Willebrand disease, sodium, bleeding time, factor VIII activity, ristocetin cofactor activity and von Willebrand antigen during treatment (DDAVP Injection label). The 2021 guideline includes recommendations on desmopressin trials to determine therapy (Connell et al., 2021).
• Blood pressure and pulse — During the IV infusion (DDAVP Injection label).
• Kidney function — The labels contraindicate it below a creatinine clearance of 50 mL/min and note that monitoring kidney function may be useful in older patients (DDAVP Tablets label).
• Which tests fit a given person — A question for a licensed healthcare provider. This page can’t answer it.

Commonly Stacked With

Desmopressin’s tested pairings are mostly medical: with a bed alarm or bladder drugs in bedwetting (Hahn et al., 2025), with alpha-blockers in men with nocturia (Han et al., 2018), and with factor VIII concentrate in hemophilia A (Romano et al., 2024). One study gave it together with a peptide on this site, hexarelin, to study hormone release in healthy men (Korbonits et al., 1999). Other overlaps were unplanned: people on desmopressin who were also on growth hormone (Smith et al., 2003; Misra et al., 2010) or gonadotropin therapy (Wen et al., 2021), or who started GLP-1 drugs for diabetes or weight loss (Nakhleh et al., 2024; Caputo, 2026). PubMed searches of October 4 and 5, 2026 found no study testing desmopressin together with BPC-157, TB-500, thymosin peptides, ipamorelin, CJC-1295, sermorelin, tesamorelin, GHRP-2, GHRP-6, MK-677, GHK-Cu, melanotan, PT-141, kisspeptin or gonadorelin (the searches are listed under References).

→ Peptide Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching desmopressin often also look at these:

Next Steps

References

1. Zaoral M, Kolc J, Šorm F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-γ-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin. Collect Czech Chem Commun. 1967;32(3):1250-1257. DOI: 10.1135/cccc19671250.
2. Vávra I, Machová A, Holecek V, Cort JH, et al. Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet. 1968;1(7549):948-952. PMID: 4171585. DOI: 10.1016/s0140-6736(68)90904-5.
3. Manning M, Misicka A, Olma A, Bankowski K, et al. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol. 2012;24(4):609-628. PMID: 22375852. DOI: 10.1111/j.1365-2826.2012.02303.x. (Full text at PMC3490377, read October 4, 2026: desmopressin “first synthesised by the Zaoral et al. in Prague and later licensed to Ferring”; rat antidiuretic/pressor ratio 3000, against 0.9 for vasopressin.)
4. Marek J, Loutocký A, Pacovský V, Zaoral M. Ten-year experience with DDAVP in treatment of diabetes insipidus. Endokrinologie. 1978;72(2):188-194. PMID: 738214.
5. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet. 1977;1(8017):869-872. PMID: 67283. DOI: 10.1016/s0140-6736(77)91197-7.
6. Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost. 1996;76(5):692-696. PMID: 8950775.
7. Mannucci PM, Siboni SM. Factor VIII and von Willebrand factor are wavering proteins: the basis for the therapeutic development of desmopressin. Res Pract Thromb Haemost. 2024;8(2):102369. PMID: 38595335. DOI: 10.1016/j.rpth.2024.102369.
8. Arima H, Cheetham T, Christ-Crain M, Cooper D, et al. Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus. J Clin Endocrinol Metab. 2022;108(1):1-3. PMID: 36355385. DOI: 10.1210/clinem/dgac547.
9. Atila C, Refardt J, Christ-Crain M. Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic. J Clin Endocrinol Metab. 2026;111(4):922-937. PMID: 41363127. DOI: 10.1210/clinem/dgaf651.
10. Atila C, Loughrey PB, Garrahy A, Winzeler B, et al. Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Lancet Diabetes Endocrinol. 2022;10(10):700-709. PMID: 36007536. DOI: 10.1016/S2213-8587(22)00219-4.
11. Juul KV, Bichet DG, Nørgaard JP. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine. 2011;40(1):67-74. PMID: 21626284. DOI: 10.1007/s12020-011-9492-z. (Article page at link.springer.com, read October 5, 2026: “This work was supported by a grant from Ferring Pharmaceutical”; Juul and Nørgaard listed at Ferring Pharmaceuticals A/S.)
12. Blanco EJ, Lane AH, Aijaz N, Blumberg D, Wilson TA. Use of subcutaneous DDAVP in infants with central diabetes insipidus. J Pediatr Endocrinol Metab. 2006;19(7):919-925. PMID: 16995572. DOI: 10.1515/jpem.2006.19.7.919.
13. Behan LA, Sherlock M, Moyles P, Renshaw O, et al. Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study. Eur J Endocrinol. 2015;172(3):243-250. PMID: 25430399. DOI: 10.1530/EJE-14-0719.
14. Pedersen AN, Andreassen M, Rasmussen AK, Krogh J. Desmopressin Dose Requirements in Adults with Congenital and Acquired Central Diabetes Insipidus. Horm Metab Res. 2024;56(3):206-213. PMID: 37879354. DOI: 10.1055/a-2198-7207.
15. Christensen A, Parth A, Kotak M, Radosavjevic D, et al. Open-Label, Balanced, Randomized, Single-Dose, Three-Treatment, Three-Sequence, Three-Period, Three-Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution. Clin Pharmacol Drug Dev. 2026;15(8):e70086. PMID: 42548160. DOI: 10.1002/cpdd.70086. (Full text at PMC13434358, read October 4, 2026: the solution is Eton Pharmaceuticals’, and the study was supported by Eton.)
16. Fralick M, Schneeweiss S, Wallis CJD, Jung EH, Kesselheim AS. Desmopressin and the risk of hyponatremia: A population-based cohort study. PLoS Med. 2019;16(10):e1002930. PMID: 31634354. DOI: 10.1371/journal.pmed.1002930.
17. Achinger SG, Arieff AI, Kalantar-Zadeh K, Ayus JC. Desmopressin acetate (DDAVP)-associated hyponatremia and brain damage: a case series. Nephrol Dial Transplant. 2014;29(12):2310-2315. PMID: 25107337. DOI: 10.1093/ndt/gfu263.
18. Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol. 2007;178(1):24-30. PMID: 17574054. DOI: 10.1016/j.juro.2007.03.015.
19. Hahn D, Stewart F, Raman G. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev. 2025;7(7):CD002112. PMID: 40728007. DOI: 10.1002/14651858.CD002112.pub2.
20. Sand PK, Dmochowski RR, Reddy J, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190(3):958-964. PMID: 23454404. DOI: 10.1016/j.juro.2013.02.037.
21. Weiss JP, Herschorn S, Albei CD, van der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190(3):965-972. PMID: 23454402. DOI: 10.1016/j.juro.2012.12.112.
22. Kaminetsky J, Fein S, Dmochowski R, MacDiarmid S, et al. Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double-Blind, Placebo Controlled, Phase 3 Trials. J Urol. 2018;200(3):604-611. PMID: 29654805. DOI: 10.1016/j.juro.2018.04.050. (PubMed affiliations: Fein S and Cheng M, Serenity Pharmaceuticals LLC.)
23. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. Desmopressin for treating nocturia in men. BJU Int. 2018;122(4):549-559. PMID: 29489052. DOI: 10.1111/bju.14183.
24. Saito M, Tahara A, Sugimoto T. 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol. 1997;53(11):1711-1717. PMID: 9264324. DOI: 10.1016/s0006-2952(97)00070-1.
25. Kaufmann JE, Oksche A, Wollheim CB, Günther G, et al. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000;106(1):107-116. PMID: 10880054. DOI: 10.1172/JCI9516.
26. Romano LGR, Schütte LM, van Hest RM, Meijer K, et al. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients. Haemophilia. 2024;30(2):355-366. PMID: 38343113. DOI: 10.1111/hae.14946.
27. Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325. PMID: 33570647. DOI: 10.1182/bloodadvances.2020003264.
28. Desborough MJ, Oakland K, Brierley C, Bennett S, et al. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev. 2017;7(7):CD001884. PMID: 28691229. DOI: 10.1002/14651858.CD001884.pub3.
29. Desborough MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, et al. Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial. Lancet Neurol. 2023;22(7):557-567. PMID: 37353276. DOI: 10.1016/S1474-4422(23)00157-6.
30. Weingartner H, Gold P, Ballenger JC, Smallberg SA, et al. Effects of vasopressin on human memory functions. Science. 1981;211(4482):601-603. PMID: 7455701. DOI: 10.1126/science.7455701.
31. Beckwith BE, Till RE, Schneider V. Vasopressin analog (DDAVP) improves memory in human males. Peptides. 1984;5(4):819-822. PMID: 6494028. DOI: 10.1016/0196-9781(84)90028-7.
32. Jenkins JS, Mather HM, Coughlan AK. Effect of desmopressin on normal and impaired memory. J Neurol Neurosurg Psychiatry. 1982;45(9):830-831. PMID: 7131017. DOI: 10.1136/jnnp.45.9.830.
33. Guard O, Marchal G, Graule A, Dumas R, D'Athis P. Effects of vasopressin and desmopressin on memory. A double-blind study in 40 healthy volunteers. Neuropsychobiology. 1986;15(2):80-83. PMID: 3762902. DOI: 10.1159/000118246.
34. Peabody CA, Davies H, Berger PA, Tinklenberg JR. Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's disease. Neurobiol Aging. 1986;7(4):301-303. PMID: 3528891. DOI: 10.1016/0197-4580(86)90011-4.
35. Leng G, Leng RI, Maclean S. The vasopressin-memory hypothesis: a citation network analysis of a debate. Ann N Y Acad Sci. 2019;1455(1):126-140. PMID: 31119764. DOI: 10.1111/nyas.14110.
36. Sanchis-Gomar F, Martinez-Bello VE, Nascimento AL, Perez-Quilis C, et al. Desmopresssin and hemodilution: implications in doping. Int J Sports Med. 2010;31(1):5-9. PMID: 19885778. DOI: 10.1055/s-0029-1239500.
37. Nakhleh A, Shehadeh N, Mansour B. GLP-1 receptor agonists may enhance the effects of desmopressin in individuals with AVP deficiency: a case series and proposed mechanism. Pituitary. 2024;27(5):731-736. PMID: 39240512. DOI: 10.1007/s11102-024-01451-7.
38. Caputo C. Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency. JCEM Case Rep. 2026;4(5):luag110. PMID: 42051284. DOI: 10.1210/jcemcr/luag110.
39. Korbonits M, Kaltsas G, Perry LA, Putignano P, et al. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab. 1999;84(7):2489-2495. PMID: 10404825. DOI: 10.1210/jcem.84.7.5811.
40. Smith JC, Lane HA, Lewis J, Dann S, et al. Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin. J Clin Endocrinol Metab. 2003;88(5):2152-2156. PMID: 12727969. DOI: 10.1210/jc.2002-021618.
41. Misra S, Johnston LB, Drake WM. Severe hypernatraemia associated with growth hormone replacement therapy in a patient with septo-optic dysplasia. Pituitary. 2010;13(2):186-188. PMID: 18814036. DOI: 10.1007/s11102-008-0144-0.
42. Wen J, Jiangfeng M, Min N, Xi W, et al. Desmopressin Suppresses Gonadotropin-Induced Spermatogenesis in Patients With Pituitary Stalk Interruption Syndrome: A Retrospective, Single-Center Cohort Study. Endocr Pract. 2021;27(2):124-130. PMID: 33563411. DOI: 10.1016/j.eprac.2020.08.001.
43. Ferring Pharmaceuticals Inc. DDAVP Tablets (desmopressin acetate) prescribing information (Rev. 07/2020). DailyMed set ID 6d55baa9-2b62-469c-93ae-3909ab249332 (version 7, published December 10, 2025). dailymed.nlm.nih.gov. Read October 4, 2026.
44. Ferring Pharmaceuticals Inc. DDAVP Injection (desmopressin acetate) for intravenous or subcutaneous use, prescribing information, with boxed warning: hyponatremia. DailyMed set ID 651f6fee-a2c7-431b-8d5d-58b156c72244 (version 15, effective September 28, 2022). dailymed.nlm.nih.gov. Read October 4, 2026.
45. Apotex Corp. Desmopressin nasal spray, USP, 10 mcg per 0.1 mL, prescribing information. DailyMed set ID 1ac423b8-27a6-4cef-4a82-c50bf81b4f49 (version 13, published September 14, 2026). dailymed.nlm.nih.gov. Read October 4, 2026.
46. Ferring Pharmaceuticals Inc. Stimate (desmopressin acetate) nasal spray prescribing information (revised 07/2026). DailyMed set ID f5ada39c-20ed-4500-9dce-1e4ab642a358 (version 3, published July 24, 2026). dailymed.nlm.nih.gov. Read October 4, 2026.
47. Eton Pharmaceuticals, Inc. Desmoda (desmopressin acetate) oral solution prescribing information (revised 02/2026). DailyMed set ID 4c0e1356-d14f-cfb4-e063-6294a90acd27 (version 1, published March 5, 2026). dailymed.nlm.nih.gov. Read October 4, 2026.
48. Ferring Pharmaceuticals Inc. Nocdurna (desmopressin acetate) sublingual tablets prescribing information, with boxed warning: hyponatremia (revised 6/2018). NDA 022517. accessdata.fda.gov/drugsatfda_docs/label/2018/022517s000lbl.pdf. Read October 4, 2026.
49. Serenity Pharmaceuticals, LLC. Noctiva (desmopressin acetate) nasal spray prescribing information, with boxed warning: hyponatremia (revised 03/2017). NDA 201656. accessdata.fda.gov/drugsatfda_docs/label/2017/201656lbl.pdf. Read October 4, 2026.
50. FDA. Drugs@FDA through openFDA (api.fda.gov/drug/drugsfda.json), search “desmopressin”: 38 applications, with sponsors, products, marketing status and approval dates (DDAVP NDA 017922, original approval February 21, 1978). Read October 4, 2026.
51. FDA. Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2023;88(24):7736-7738 (FR Doc. 2023-02442; lists DDAVP (Needs No Refrigeration) nasal spray 0.01 mg/spray, NDA 017922). federalregister.gov. Read October 4, 2026.
52. FDA. Enforcement reports D-1504-2020, D-1505-2020 and D-1506-2020: Class I recalls by Ferring, initiated July 21, 2020, of DDAVP Nasal Spray 10 mcg/0.1 mL, a desmopressin acetate nasal spray 10 mcg/0.1 mL and Stimate nasal spray 1.5 mg/mL; reason “Superpotent Drug” (openFDA drug/enforcement). api.fda.gov. Read October 4, 2026.
53. FDA. Drug Shortages: Desmopressin Acetate Spray, status current, initial posting March 12, 2021; Ferring presentations unavailable (reverified May 1, 2026), a generic presentation available (updated September 16, 2026) (openFDA drug/shortages, data of October 2, 2026). api.fda.gov. Read October 4, 2026.
54. FDA. National Drug Code Directory: desmopressin bulk-ingredient listings, 12 labelers, one listed as “bulk ingredient for human prescription compounding” (openFDA drug/ndc, data of October 2, 2026). api.fda.gov. Read October 4, 2026.
55. US Code. 21 U.S.C. 353a (section 503A, pharmacy compounding), subsection (b)(1)(A)(i); and 21 U.S.C. 353b (section 503B, outsourcing facilities), subsection (a)(2)(A). law.cornell.edu/uscode/text/21/353a and law.cornell.edu/uscode/text/21/353b. Read October 4, 2026.
56. US Code of Federal Regulations. 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A, and 216.24, Drug products withdrawn or removed from the market for reasons of safety or effectiveness. ecfr.gov. Read October 4, 2026.
57. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1–3). Updated May 14, 2026. fda.gov/media/94155/download.
58. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories 1–3). Updated March 21, 2025. fda.gov/media/94164/download.
59. PMDA (Pharmaceuticals and Medical Devices Agency, Japan). List of Approved Products, New Drugs: April 2004 to February 2026 (“List of Approved Drugs”), entries for desmopressin acetate hydrate: March 30, 2012, Minirinmelt OD Tablets 120 μg and 240 μg (Ferring Pharmaceuticals Co., Ltd.), a new route of administration for nocturnal enuresis associated with decreased urine osmolality or urinary specific gravity; December 21 and 25, 2012, a new indication for central diabetes insipidus (Minirinmelt OD Tablets 120 and 240 μg, and the new 60 μg tablet); June 18, 2019, Minirinmelt OD Tablets 25 μg and 50 μg, a new indication for nocturia due to nocturnal polyuria in males. pmda.go.jp/files/000281190.pdf. Read October 5, 2026.
60. World Anti-Doping Agency. Prohibited List 2026 (in effect January 1, 2026). S5, Diuretics and masking agents. wada-ama.org.
61. ClinicalTrials.gov. Records NCT01223937 (COMFORT, Phase 3, sponsor Ferring Pharmaceuticals, women with nocturia, desmopressin 25 μg or placebo for 3 months, completed; the record links its results to Sand et al., 2013), NCT01262456 (Phase 3, sponsor Ferring Pharmaceuticals, men with nocturia, desmopressin 50 or 75 μg or placebo for 3 months, completed; the record links its results to Weiss et al., 2013), NCT01357356 (SER120 DB3, Phase 2/3, sponsor Serenity Pharmaceuticals, completed), NCT01900704 (SER120 DB4, Phase 3, sponsor Serenity Pharmaceuticals, completed), NCT06020495 (DASSOH, Phase 3, Assistance Publique – Hôpitaux de Paris, 260 planned, recruiting; estimated primary completion September 30, 2026; last updated May 23, 2025), NCT06337838 (BRACKETS pilot, Phase 3, Hamilton Health Sciences, 100 planned, recruiting), NCT05467033 (STOP-BLEED, Phase 3, Medical University of Bialystok, 424 planned, recruiting; estimated primary completion August 31, 2026; last updated May 8, 2025), NCT07012837 (REDES-BLEED, Phase 3, Imam Abdulrahman Bin Faisal University, 112 planned, not yet recruiting; start date July 2025; last updated June 10, 2025), NCT07712328 (Phase 4, 152 planned, enrolling by invitation), NCT06635629 (Phase 2, NIDDK, 140 planned, recruiting), NCT04569591 (NINDS, phase not applicable, 22 planned, recruiting; estimated primary completion February 26, 2028) and NCT07855315 (randomized, phase not applicable, Services Institute of Medical Sciences, Pakistan, desmopressin by nose before sinus surgery, 174 planned, not yet recruiting; estimated primary completion October 14, 2027). clinicaltrials.gov, API v2. Read October 4, 2026; re-read October 5, 2026.
62. National Library of Medicine. PubChem: Desmopressin, CID 5311065 (C46H64N14O12S2, 1069.2 g/mol); desmopressin acetate, CID 9833407 (C48H68N14O14S2, 1129.3 g/mol). pubchem.ncbi.nlm.nih.gov. Read October 4, 2026.
63. A laboratory-reagent supplier’s catalogue entry for desmopressin: freeze-dried powder, sequence Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2 with a disulfide bridge between positions 1 and 6, storage at −20 °C, “for research use only” and “not for human or animal consumption.” Read October 4, 2026. The supplier is not named: Kalios doesn’t name or link vendors.
64. Searches of October 4, 2026: PubMed, “desmopressin” (6,794 records), “Deamino Arginine Vasopressin”[Mesh] (4,571) and with “Randomized Controlled Trial”[pt] (292); PubMed, desmopressin or DDAVP in the title with memory, cognition, learning or dementia terms (33 records); desmopressin and oxytocin in the title (2 records, neither a combination study); desmopressin with BPC-157, TB-500, thymosin, ipamorelin, CJC-1295, sermorelin, tesamorelin, GHK-Cu, semaglutide, tirzepatide, melanotan, PT-141, bremelanotide, kisspeptin or gonadorelin (39 records: doping-test, drug-delivery and diagnostic papers, and the tirzepatide case report) and with semaglutide, liraglutide, tirzepatide or GLP-1 (9 records, two clinical: the case reports cited above); ClinicalTrials.gov, desmopressin as an intervention (127 studies, 16 with an active status) and as a search term (157); Drugs@FDA, DailyMed (51 labels), FDA drug shortages, enforcement reports and NDC Directory through openFDA. Searches of October 5, 2026: PubMed, desmopressin and hexarelin (11 records: the one study that gave the two together, cited above; two that gave desmopressin and a growth-hormone secretagogue as separate tests; assay papers and reviews); desmopressin with GHRP, GHRP-2, GHRP-6, pralmorelin, macimorelin, ibutamoren, MK-677 or ghrelin (14 records, none giving them together); desmopressin or DDAVP with growth hormone in the title, or with somatropin, GH-treated or GH replacement (20 records: the two co-use reports cited above, studies using desmopressin as a diagnostic test, other case reports and unrelated papers); desmopressin or DDAVP with chorionic gonadotropin, hCG, menotropins, hMG, gonadotropins in the title, or spermatogenesis (14 records: the cohort study cited above, case reports and unrelated papers); desmopressin or DDAVP in the title with insulin, testosterone, oxytocin, triptorelin, leuprolide, kisspeptin, gonadorelin, GnRH, thymosin, glutathione, methylene blue, NAD, semaglutide, liraglutide, tirzepatide, exenatide, dulaglutide, pramlintide, vasoactive intestinal peptide, clomiphene, growth hormone, hexarelin or gonadotropins (12 records: studies cited above and laboratory, assay and animal papers); ClinicalTrials.gov, the records listed above, re-read; PMDA’s list of approved new drugs, April 2004 to February 2026 (Minirinmelt OD, 2012 and 2019); PubMed, desmopressin, DDAVP or 1-deamino-8-D-arginine vasopressin with subcutaneous in the title (24 records, among them the two studies of injection under the skin cited above); ClinicalTrials.gov, “desmopressin” (157 records, 22 with an active status: six are trials of desmopressin itself with an estimated primary completion still ahead, all listed above; the rest give it in every arm, are observational, test something else, or have a primary completion date that has passed).

Related Research

• OxytocinNeurohypophyseal Nonapeptide Hormone
• VesiluteKhavinson Short-Peptide Bioregulator (Bladder)
• HexarelinGHRP (Growth Hormone-Releasing Peptide)
• HGHRecombinant Human Growth Hormone (rhGH)
• TirzepatideDual GIP/GLP-1 Receptor Agonist
• SemaglutideGLP-1 Receptor Agonist
• LiraglutideDaily GLP-1 Receptor Agonist